# Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

> **NCT03049618** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 42 (actual)

## Conditions studied

- ALK Gene Mutation
- BRAF Gene Mutation
- EGFR Gene Mutation
- Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Carcinoma
- Recurrent Head and Neck Carcinoma
- Recurrent Non-Small Cell Lung Carcinoma
- ROS1 Gene Mutation
- Stage III Non-Small Cell Lung Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Recombinant EphB4-HSA Fusion Protein

## Key facts

- **NCT ID:** NCT03049618
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-10
- **Primary completion:** 2024-09-04
- **Final completion:** 2024-09-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03049618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03049618, "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03049618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*